2 results
Approved WMOCompleted
RAD1901, a novel selective ER modulator (SERM)/selective ER degrader (SERD), has previously been demonstrated to modulate the ER in both nonclinical and clinical studies. The aim of this study is to visualise and quantify ER-binding sites during…
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…